ASXL1 mutations in primary and secondary myelofibrosis

被引：15
|
作者：
Ricci, Clara [1 ]
Spinelli, Orietta [1 ]
Salmoiraghi, Silvia [1 ]
Finazzi, Guido [1 ]
Carobbio, Alessandra [1 ]
Rambaldi, Alessandro [1 ]
机构：
[1] Osped Riuniti Bergamo, Unit Haematol, I-24100 Bergamo, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 156卷 / 03期
关键词：
ASXL1; mutations; myelofibrosis; chronic myeloproliferative neoplasms; CHRONIC MYELOMONOCYTIC LEUKEMIA; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE NEOPLASMS; GENE ASXL1;
D O I：
10.1111/j.1365-2141.2011.08865.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：404 / 407
页数：4
相关论文
共 50 条
  • [31] Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis
    Guglielmelli, Paola
    Biamonte, Flavia
    Score, Johannah
    Hidalgo-Curtis, Claire
    Cervantes, Francisco
    Maffioli, Margherita
    Fanelli, Tiziana
    Ernst, Thomas
    Winkelman, Nils
    Jones, Amy V.
    Zoi, Katerina
    Reiter, Andreas
    Duncombe, Andrew
    Villani, Laura
    Paoli, Chiara
    Bosi, Alberto
    Barosi, Giovanni
    Cross, Nicholas C. P.
    Vannucchi, Alessandro M.
    BLOOD, 2011, 118 (21) : 1212 - 1212
  • [32] PROGNOSTIC SIGNIFICANT OF ASXL1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES
    Wang, S. Y.
    Lin, Y.
    Zheng, Y.
    Wang, Z. C.
    HAEMATOLOGICA, 2016, 101 : 501 - 501
  • [33] Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
    A Tefferi
    T L Lasho
    C Finke
    N Gangat
    C A Hanson
    R P Ketterling
    A Pardanani
    Leukemia, 2018, 32 : 837 - 839
  • [34] ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis
    Abdelmagid, Maymona
    Palmer, Jeanne
    Foran, James M.
    Al-Kali, Aref
    Karrar, Omer
    Reichard, Kaaren K.
    Pardanani, Animesh D.
    Gangat, Naseema
    Tefferi, Ayalew
    BLOOD, 2023, 142
  • [35] Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
    Tefferi, A.
    Lasho, T. L.
    Finke, C.
    Gangat, N.
    Hanson, C. A.
    Ketterling, R. P.
    Pardanani, A.
    LEUKEMIA, 2018, 32 (03) : 837 - 839
  • [36] Prognostic Impact of ASXL1 Mutations in MDS and CMML
    Sallman, David
    Padron, Eric
    Vaupel, Christine
    Cluzeau, Thomas
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    Hall, Jeff
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2015, 126 (23)
  • [37] The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description
    Melikyan, A. L.
    Subortseva, I. N.
    Gilyazitdinova, E. A.
    Koloshejnova, T., I
    Egorova, E. K.
    Pustovaya, E., I
    Sudarikov, A. B.
    Abdullaev, A. O.
    Gorgidze, L. A.
    Chebotarev, D., I
    TERAPEVTICHESKII ARKHIV, 2020, 92 (07) : 95 - 99
  • [38] Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
    Helene Myrtue Nielsen
    Christen Lykkegaard Andersen
    Maj Westman
    Lasse Sommer Kristensen
    Fazila Asmar
    Torben Arvid Kruse
    Mads Thomassen
    Thomas Stauffer Larsen
    Vibe Skov
    Lise Lotte Hansen
    Ole Weis Bjerrum
    Hans Carl Hasselbalch
    Vasu Punj
    Kirsten Grønbæk
    Scientific Reports, 8
  • [39] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
    Kakosaiou, K.
    Daraki, A.
    Apostolou, P.
    Zachaki, S.
    Pagoni, M.
    Sambani, C.
    Dimitriadis, G.
    Papa, V.
    Manola, K. N.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 80 - 80
  • [40] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
    Kakosaiou, K.
    Daraki, A.
    Apostolou, P.
    Zachaki, S.
    Pagoni, M.
    Sambani, C.
    Dimitriadis, G.
    Papa, V.
    Manola, K. N.
    ANNALS OF HEMATOLOGY, 2015, 94 : S80 - S80
12345